Muttenz, Switzerland, September 22, 2026
Opterion Health AG has announced positive Phase 1 clinical results for OPT101, its investigational non-glucose-based solution for peritoneal dialysis (PD), supporting the program’s advancement into a planned Phase 2a study. The first-in-human SPARC Phase 1 study evaluated OPT101 in patients with moderate to severe chronic kidney disease and achieved its major objectives across safety, tolerability, pharmacokinetics and functional activity. The company reported that no serious adverse events, treatment discontinuations caused by adverse events, dose interruptions or concentration-limiting toxicities were observed during the study. OPT101 also demonstrated encouraging activity across the evaluated concentrations, with the highest concentration producing the greatest mean fluid removal and sodium removal during both short and long dialysis dwells. The findings provide clinical evidence supporting the continued development of OPT101 as Opterion seeks to expand treatment options for patients receiving home-based peritoneal dialysis.
SPARC Study Demonstrates Safety and Functional Activity
The SPARC Phase 1 trial investigated different concentrations of OPT101 during four-hour and eight-hour peritoneal dialysis dwells in patients with moderate or severe chronic kidney disease. According to Opterion Health, the study met its objectives, with the investigational solution demonstrating a favorable safety and tolerability profile. Importantly, the company reported no serious adverse events, treatment discontinuations due to adverse events, dose interruptions, concentration-limiting toxicities or interruptions to dose escalation. Alongside the safety findings, OPT101 showed functional activity across all evaluated concentrations. The highest concentration generated the greatest mean fluid removal during both short and long dwells, accompanied by sodium removal. These findings are particularly relevant to the development of a dialysis solution intended to provide an alternative to conventional glucose-based approaches.
OPT101 Targets Unmet Needs in Peritoneal Dialysis
Peritoneal dialysis enables people with kidney failure to receive life-sustaining treatment at home, offering greater flexibility and independence for many patients. However, conventional peritoneal dialysis relies heavily on glucose-based solutions, which can be associated with metabolic complications, weight gain and changes to the peritoneal membrane over time. Opterion Health is developing OPT101 as a non-glucose-based osmotic driver solution intended for use across both short and long dwell periods. The company says currently available non-glucose alternatives do not provide the same intended combination of non-glucose-based treatment, concentration flexibility and use across both dwell settings. OPT101 is therefore being developed to potentially expand treatment choice while addressing some limitations associated with existing peritoneal dialysis approaches.
Advertisement
The Phase 1 findings provide an important clinical foundation for evaluating whether the approach can deliver consistent benefits with repeated administration. Opterion describes OPT101 as an investigational program and has not established its safety or effectiveness as an approved treatment. Further clinical evaluation will therefore be required to determine its potential role in routine peritoneal dialysis.
Phase 2a GLOW Study to Evaluate Repeated Use
Following the SPARC results, Opterion Health plans to advance OPT101 into the Phase 2a GLOW study. The next-stage trial is expected to examine repeated administration, dose selection and broader dwell replacement, while further evaluating the functional and metabolic characteristics of OPT101 in patients with chronic kidney disease. The company intends to assess the investigational solution across more of the daily dialysis regimen, providing additional information on its performance and potential differentiation from existing approaches. The advancement comes as Opterion seeks to address longstanding limitations in peritoneal dialysis. The company notes that peritoneal dialysis currently represents a relatively small proportion of global dialysis treatment despite its potential clinical and lifestyle advantages. With chronic kidney disease continuing to create substantial demand for renal replacement therapies, innovations that could broaden home-based dialysis options remain an important area of research. OPT101’s progression from first-in-human testing to Phase 2a represents the next stage in Opterion’s clinical development strategy and will provide further evidence on whether its non-glucose-based approach can translate into meaningful advantages for people receiving peritoneal dialysis.
Source: Opterion Health press release
